Clinical trial results for
advanced non-small cell
lung cancer (NSCLC)
For adults with advanced non-small cell lung cancer (NSCLC)
Clinical trial results for
advanced non-small cell
lung cancer (NSCLC)
For adults with advanced non-small cell lung cancer (NSCLC)
Actor portrayals.
OPDIVO + YERVOY is not approved for people
younger than 18 years of age.
In a clinical trial of 719 people with previously untreated NSCLC, 361 people were given OPDIVO + YERVOY and platinum-based chemotherapy, and 358 people were given platinum-based chemotherapy.
Half the people were alive
Half the people were alive
In the primary analysis with a minimum follow-up of 8 months, people given OPDIVO + YERVOY and platinum-based chemotherapy had a 31% lower risk of dying than those given platinum-based chemotherapy.
In an analysis with a minimum follow-up of 7 months, half of the people given OPDIVO + YERVOY and platinum-based chemotherapy lived 7 months without their tumors worsening compared to 5 months for people given platinum-based chemotherapy.
OPDIVO + YERVOY and platinum-based chemotherapy will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For certain adults with advanced non-small cell lung cancer (NSCLC)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.